Company Overview
Company Type: Private Company
Website: www.altasciences.com
Number of Employees: 600
Year Founded: 1992
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Altasciences Company, Inc. operates as an early phase contract research organization (CRO) which provides early phase clinical research and development services to biopharmaceutical and generic companies. The company offers medical writing, biostatistics, data management, and bioanalysis services. In addition, it provides phase I/II drug development, bioequivalence and bioavailability studies, and statistical programming services. Altasciences Company, Inc. has a strategic alliance with Altreos Research Partners; and a strategic collaboration agreement Amador Bioscience. Altasciences Company, Inc. was founded in 1992 and is headquartered in Laval, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 166.4
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 600
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Perkin, Christopher 
Chief Executive Officer
Rodriguez, Mariano 
Executive VP & CFO
Mason, Steve 
Co-Chief Operating Officer
Raigneau, Marie-Hélène 
Co-Chief Operating Officer
Konidas, Catherine 
Chief Administrative Officer
Gregoire, David 
Chief Quality & Compliance Officer
Cabana, Julie-Ann 
Chief Marketing Officer
Francisco, Joseph A.
Chief Toxicologist
Morelli, Gaetano 
Chief Medical Officer
Sabelli, Robert 
Chief Business Development Officer
Setnik, Beatrice 
Chief Scientific Officer


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
575 Armand-Frappier Boulevard | Laval, QC | H7V 4B3 | Canada
Fax: 450 973-6077

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Novo Holdings A/S
Feb-22-2021
Majority
100.00 %
-

Prior Investors
Audax Management Company, LLC, Kilmer Capital Partners, Kilmer Van Nostrand Co. Limited


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Sinclair Research Center, LLC
Sinclair Research Center, LLC provides biomedical research services on species in the areas of applied human and veterinary medicine. The company was founded in 1964 and is based in Auxvasse, Missouri.

United States and Canada
Life Sciences Tools and Services
0.00
-
-
Calvert Laboratories, Inc.
Calvert Laboratories, Inc. engages in the design and submission of preclinical development programs to various regulatory agencies worldwide. It offers lead identification and lead optimization services; and preclinical services in the areas of toxicology, pharmacology, immunology, pharmacokinetics/TK/ADME, and pharmacokinetics/toxicokinetics. The company also provides analytical and bioanalytical evaluation services; discovery services that include efficacy testing, autoimmune/inflammation assays and models, anti-cancer models, anti-infective models, and immunomodulations; and telemetry, pathology, and bioanalytical services. In addition, it offers screening services that include single and multi-dose PK profiling, bioavailability/dose proportionality, mass balance, elimination/excretion, and organ distribution studies; Ex vivo services, which include blood cell partitioning and plasma protein binding studies; and in vitro ADME services, including include drug-metabolizing enzyme inhibition and induction, reaction phenotyping, metabolic stability, metabolite characterization and identification, liver toxicity, and transporter studies. Calvert Laboratories, Inc. was formerly known as Calvert Preclinical Services, Inc. and changed its name to Calvert Laboratories, Inc. in February 2003. The company was founded in 1969 and is based in Cary, North Carolina. As of May 5, 2021, Calvert Laboratories, Inc. operates as a subsidiary of Altasciences Company, Inc.

United States and Canada
Life Sciences Tools and Services
14.00
-
-
WCCT Global, LLC
WCCT Global, LLC is a pharmaceutical contract research organization that offers outsourced early drug development and late phase services to pharmaceutical, biotechnology, and medical device industries worldwide. The company’s CRO services include project management, site management, study start up, clinical monitoring, data management, pharmacovigilance, biostatistics, medical writing, medical monitoring and safety, and regulatory affairs. It offers services in the areas of cardiovascular, gastrointestinal, infectious disease and vaccines, ophthalmology, respiratory, and immunology and allergy. WCCT Global, LLC was formerly known as West Coast Clinical Trials, LLC. The company was founded in 1998 and is based in Cypress, California. As of February 12, 2021, WCCT Global, LLC operates as a subsidiary of Altasciences Company, Inc.

United States and Canada
Life Sciences Tools and Services
39.00
-
-
Alliance Contract Pharma LLC
Alliance Contract Pharma LLC engages in contract manufacturing of liquid and powder filled capsule or clinical trials and post-clinical commercial use. The company provides laboratory services. The company was founded in 2008 and is based in Harleysville, Pennsylvania. As of February 27, 2020, Alliance Contract Pharma LLC operates as a subsidiary of Altasciences Company, Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-
Algorithme Pharma USA Inc.
Algorithme Pharma USA Inc. provides early stage clinical research services. The company offers support services including large and small molecule bioanalysis, data management, biostatistics, regulatory support, clinical pharmacology, and project management. It caters to generic, biotechnology, and pharmaceutical companies. The company was founded in 2008 and is headquartered in Fargo, North Dakota. Algorithme Pharma USA Inc. operates as a subsidiary of Altasciences Company Inc.

United States and Canada
Life Sciences Tools and Services
3.00
-
-
Algorithme Pharma, Inc.
Algorithme Pharma, Inc. provides early stage clinical research services. It offers support services including large and small molecule bioanalysis, data management, biostatistics, regulatory support, clinical pharmacology, and project management. The company conducts over 200 clinical trials annually in phase I/IIa, bioequivalence, and bioanalysis which is preclinical to phase I-IV. It caters to generic, biotechnology, and pharmaceutical companies. The company was founded in 1992 and is based in Laval, Canada. Algorithme Pharma, Inc. operates as a subsidiary of Altasciences Company Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-04-2022
Jan-04-2022
Merger/Acquisition
Buyer
Sinclair Research Center, LLC
Altasciences Company, Inc.

-
May-05-2021
May-05-2021
Merger/Acquisition
Buyer
Calvert Laboratories, Inc.
Altasciences Company, Inc.

-
Feb-22-2021
Mar-25-2021
Merger/Acquisition
Target
Altasciences Company, Inc.
Novo Holdings A/S
Audax Management Company, LLC
-
Feb-19-2021
Feb-12-2021
Merger/Acquisition
Buyer
WCCT Global, LLC
Altasciences Company, Inc.
Medivate Partners LLC (nka:LINEA Investment, Inc.)
-
Feb-27-2020
Feb-27-2020
Merger/Acquisition
Buyer
Alliance Contract Pharma LLC
Altasciences Company, Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-30-2023
Product-Related Announcements
Altasciences Completes Successful Phase I Trial of Ischemix' Novel Compound for Treatment of Traumatic Brain Injury (Tbi)
Feb-14-2023
Business Expansions
Altasciences Company, Inc. Expands Laboratory Capabilities in Columbia
Oct-19-2022
Business Expansions
Altasciences Expands Laboratory Capabilities in Columbia
Oct-14-2022
Executive/Board Changes - Other
Altasciences Company, Inc. Announces Executive Appointments
Sep-20-2022
Client Announcements
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing Ht-Tbi for Traumatic Brain Injury and Stroke

M&A Advisors
Blake, Cassels & Graydon LLP, Edgemont Capital Partners, L.P., Fairmount Partners LP, Fredrikson & Byron P.A., Goodwin Procter LLP, Harris Williams LLC, Kirkland & Ellis LLP, Rothschild & Co SCA (ENXTPA:ROTH)


Advisors
M&A Advisors
Blake, Cassels & Graydon LLP, Edgemont Capital Partners, L.P., Fairmount Partners LP, Fredrikson & Byron P.A., Goodwin Procter LLP, Harris Williams LLC, Kirkland & Ellis LLP, Rothschild & Co SCA (ENXTPA:ROTH)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 08:27 AM
Altasciences Company, Inc.
Altasciences Co Inc
Reports
467
GlobalData

Jul 21, 2023 05:31 AM
Altasciences Company, Inc.
Altasciences Co Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
297
GlobalData

Jun 28, 2023 04:14 AM
Altasciences Company, Inc.
Altasciences Co Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
469
GlobalData

Jun 28, 2023 02:05 AM
Altasciences Company, Inc.
Altasciences Co Inc
Reports
455


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
INDV-2000 (Future)


Upcoming Events
Date/Time
Type
Nov-12-2023
Conferences
Nov-28-2023
Conferences
* Future Events are subject to change.

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Perkin, Christopher 
Chief Executive Officer
-
450 973-6077

Rodriguez, Mariano 
Executive VP & CFO
-
450 973-6077

Mason, Steve 
Co-Chief Operating Officer
-
450 973-6077

Raigneau, Marie-Hélène 
Co-Chief Operating Officer
-
450 973-6077
mhraigneau@altasciences.com
Konidas, Catherine 
Chief Administrative Officer
(450) 973-6077
450 973-6077
ckonidas@algopharm.com
Gregoire, David 
Chief Quality & Compliance Officer
-
450 973-6077

Cabana, Julie-Ann 
Chief Marketing Officer
(913) 304-4505
450 973-6077
jcabana@vinceandassociates.com
Francisco, Joseph A.
Chief Toxicologist
-
450 973-6077

Morelli, Gaetano 
Chief Medical Officer
-
450 973-6077

Sabelli, Robert 
Chief Business Development Officer
-
450 973-6077

Setnik, Beatrice 
Chief Scientific Officer
-
450 973-6077

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
